Italian anti Covid vaccine, that’s why Reithera snorts on the government
State intervention in Reithera, the Italian company that is experimenting with the anti Covid vaccine, has not yet materialized despite the announcements. All the details
“Phase one of the trials ended on 90 volunteers and went very well. The second? For now we do not have the resources "Antonella Folgori, biologist, president of Reithera (the company based in Castel Romano controlled by a Swiss company) opens her arms.
THE DIFFERENCES BETWEEN REITHERA, MODERNA, BIONTECH AND MORE
Note Repubblica : “Modern biotech, financed with 2 billion dollars by the White House, is fueling vaccination in the US, leaving Europe in the background. BioNTech from Germany provided 30 million extra doses to her country, which had helped her with 400 million euros. And London rushed yesterday to approve the Oxford vaccine, while the Italian vials remain in the freezer. The 5 million euros from the Lazio Region, the 3 from the Ministry of University and Research, the collaboration with Spallanzani for tests and the 12 million invested by Reithera were enough to get here ”.
THE WORDS OF REITHERA IN REPUBLIC
«But now, right now, we would need a shot» Folgori tells Repubblica : «We will be able to finish the new wing to bring the capacity to 10 million doses per month. But we cannot support phases 2 and 3 of the trials, nor the production costs »adds Stefano Còlloca, who leads the technological development.
WHAT ARCHURI SAID
"The state will support Reithera" had promised in September the commissioner Domenico Arcuri, suggesting a public entry into the company's capital, recalls today the newspaper of the Gedi group directed by Maurizio Molinari. "The discussions are underway," says Colloca diplomatically, who sees the pines and clouds in the direction of the Lazio coast from the window, but alongside his colleagues he has collaborated with Oxford since 2005 on a vaccine for malaria, he has signed the vaccine for Ebola together National Institutes of Health Americans and has co-authorship of the syncytial virus vaccine being tested for Glaxo.
DOES THE STATE ENTER THE CAPITAL OF REITHERA?
The state, in effect, is ready to enter the company's capital. As Il Sole 24 Ore wrote days ago, in the August decree the Conte government has put on the plate up to 380 million between this year and next, managed by Commissioner Arcuri, to ensure that the State can enter the share capital of companies that produce vaccines and anti Covid therapies. “An opportunity that Arcuri should soon realize for Reithera”, underlined the Confindustria newspaper
FINANCING ARRIVED FROM THE LAZIO REGION AND THE GOVERNMENT
In fact, the government has already bet on the Reithera vaccine. In recent months, for the company to accelerate on the anti Covid vaccine, 8 million euros have been allocated: 3 million euros have come from the Ministry of University and Scientific Research and 5 million have been paid by the Lazio Region.
"The memorandum of understanding was signed between the president of the Lazio Region, Nicola Zingaretti, the Minister of Health, Roberto Speranza, the Minister of University and Scientific Research, Gaetano Manfredi, the National Research Council and the IRCCS" Spallanzani ”, for the identification of a vaccine against COVID-19. For the realization of this objective, 8 million euros have been allocated, 5 million from the Lazio Region, transferred to Spallanzani, and 3 million from the Ministry of University and Scientific Research ”, announced a note from the Lazio Region weeks ago .
THE BIRTH OF REITHERA
Founded in 2014 by a former Okairos team, the Rome-based company deals with the development, production and clinical testing of adeno-vector vaccines of non-human origin. Among the diseases that are being worked on in the laboratories, now transferred to Naples (the GPM production center in Rome), are hepatitis C, malaria, HIV, respiratory syncytial virus and Ebola. Okairos, once acquired by Gsk, changed its name to Reithera.
SWISS CONTROL
The company, chaired by Antonella Folgori, head of immunology and founder of Okairos and formerly in Irbm, is owned by Keires Ag, a financial sector company based in Basel.
THE NUMBERS OF THE BIOTECHNOLOGY COMPANY
Reithera closed 2019 with revenues of 19,565,923 euros, up compared to 14,223,015 euros in 2018. 2019 profit more than tripled: 2,244,495 euros, compared to 664,858 in the previous year. Total production costs amounted to 16,680,460.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/economia/vaccino-italiano-anti-covid-ecco-perche-reithera-sbuffa-sul-governo/ on Thu, 31 Dec 2020 10:14:48 +0000.